Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Transplantation Behavior Rejection, Psychology Social Behavior

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients undergoing their first kidney transplant
Male or female age 18 to 65 years

Exclusion criteria

Patients in need of second kidney transplant or multi-organ transplants.

Treatment and study plan

FTY720

Drug

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Important dates

Study start: 2005
Primary completion: 2006
Study completion: 2006
First posted: Dec 21, 2004
Registry last updated: Jun 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed